RCAG
TVTX icon

Rehmann Capital Advisory Group’s Travere Therapeutics TVTX Stock Holding History

Rehmann Capital Advisory Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-33
Closed -$948 – 2104
2018
Q3 		$948 Hold
33
– – ﹤0.01% 1991
2018
Q2 		$900 Buy
+33
New +$879 ﹤0.01% 1993

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Rehmann Capital Advisory Group's TVTX Position: Q4 2018 in Review

Rehmann Capital Advisory Group sold out of Travere Therapeutics (TVTX) in Q4 2018, closing a stake of 33 shares — an estimated $948 sold.

Rehmann Capital Advisory Group first reported a position in TVTX in Q2 2018 and held it in 2 quarters. The position peaked at $948 in Q3 2018. 130 funds tracked by Wall St. Rank hold TVTX as of Q4 2018.

  • Rehmann Capital Advisory Group reported no remaining Travere Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Rehmann Capital Advisory Group sold 33 Travere Therapeutics shares in Q4 2018, an estimated $948.
  • Rehmann Capital Advisory Group first reported a position in Travere Therapeutics in Q2 2018 and held it in 2 quarters.
  • Rehmann Capital Advisory Group's Travere Therapeutics position peaked at $948 in Q3 2018.
  • 130 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2018.

Based on Rehmann Capital Advisory Group's 13F filing for Q4 2018, filed 12 Feb 2019.